Bicycle Therapeutics (NASDAQ:BCYC) Shares Up 6% – What’s Next?

Bicycle Therapeutics plc (NASDAQ:BCYC)’s stock price was up 6% on Wednesday . The company traded as high as $10.60 and last traded at $10.81. Approximately 4,893 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 293,263 shares. The stock had previously closed at $10.20.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Stephens reaffirmed an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday. JMP Securities lowered their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, B. Riley lowered their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Stock Down 7.4 %

The stock has a market cap of $664.91 million, a P/E ratio of -2.93 and a beta of 1.12. The firm’s 50-day moving average is $12.44 and its two-hundred day moving average is $18.55.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.16) EPS. Analysts anticipate that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at approximately $482,190. This represents a 7.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Alistair Milnes sold 4,578 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the transaction, the chief operating officer now directly owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. This represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. L & S Advisors Inc boosted its position in shares of Bicycle Therapeutics by 2.4% in the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after acquiring an additional 1,400 shares during the period. Assetmark Inc. acquired a new stake in Bicycle Therapeutics in the 3rd quarter worth $34,000. JPMorgan Chase & Co. grew its position in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares during the period. Finally, Barclays PLC raised its position in shares of Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after buying an additional 2,345 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.